Upgrade to SI Premium - Free Trial

Pharvaris (PHVS)

38.08 +0.02 (0.05%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/18/26)

Latest Headlines

Form 144 Pharvaris N.V. Filed by: Abele Stefan Andreas September 15, 2026 6:06 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Glassman Robert September 15, 2026 4:44 PM - SEC Filing Form 4 Pharvaris N.V. For: Sep 11 Filed by: Lu Peng September 15, 2026 2:30 PM - SEC Filing Form 4 Pharvaris N.V. For: Sep 14 Filed by: Modig Berndt September 15, 2026 2:15 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Souverijns Wim September 14, 2026 6:26 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Modig Berndt September 14, 2026 4:49 PM - SEC Filing Form 4 Pharvaris N.V. For: Sep 10 Filed by: Lesage Anne September 14, 2026 12:30 PM - SEC Filing Cantor Fitzgerald Reiterates Overweight Rating on Pharvaris B.V. (PHVS) September 14, 2026 9:57 AM - StreetInsider Form 4 Pharvaris N.V. For: Sep 09 Filed by: Glassman Robert September 11, 2026 12:25 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lesage Anne September 10, 2026 4:49 PM - SEC Filing Pharvaris B.V. (PHVS) PT Raised to $44 at Guggenheim September 10, 2026 7:06 AM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $62 at Morgan Stanley September 9, 2026 7:54 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS) September 9, 2026 7:27 AM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $62 at RBC Capital September 9, 2026 7:23 AM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $65 at Wells Fargo September 9, 2026 5:50 AM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $79 at Citizens on Agent Trial Success September 9, 2026 4:12 AM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $75 at Oppenheimer September 8, 2026 2:47 PM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $65 at Cantor Fitzgerald September 8, 2026 10:43 AM - StreetInsider Pharvaris HAE drug hits 83% attack rate cut in phase 3 trial September 8, 2026 6:50 AM - StreetInsider Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks September 8, 2026 6:50 AM - StreetInsider Pharvaris presents deucrictibant data at Bradykinin Symposium 2026 September 3, 2026 6:51 AM - StreetInsider Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 September 3, 2026 6:50 AM - StreetInsider Form 4 Pharvaris N.V. For: Aug 14 Filed by: Modig Berndt August 18, 2026 11:50 AM - SEC Filing Form SCHEDULE 13G/A Pharvaris N.V. Filed by: GENERAL ATLANTIC, L.P. August 14, 2026 8:52 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Modig Berndt August 14, 2026 4:38 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS) August 14, 2026 6:46 AM - StreetInsider Form 4 Pharvaris N.V. For: Aug 11 Filed by: Lu Peng August 13, 2026 4:37 PM - SEC Filing Pharvaris B.V. (PHVS) PT Raised to $52 as RBC Capital Sees Upside August 13, 2026 7:29 AM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $40 at Guggenheim August 13, 2026 6:43 AM - StreetInsider Pharvaris B.V. (PHVS) PT Raised to $75 at Citizens: Has Cash Runway Into 2028 August 13, 2026 4:04 AM - StreetInsider Form 6-K Pharvaris N.V. For: Jun 30 August 12, 2026 6:51 AM - SEC Filing Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update August 12, 2026 6:50 AM - StreetInsider Pharvaris publishes AAE-C1INH disease burden study in Frontiers in Immunology August 6, 2026 6:51 AM - StreetInsider Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology August 6, 2026 6:50 AM - StreetInsider Form SCHEDULE 13G/A Pharvaris N.V. Filed by: LSP V Cooperatieve U.A. July 31, 2026 7:23 AM - SEC Filing Pharvaris publishes review on bradykinin B2 receptor as therapy target July 22, 2026 6:50 AM - StreetInsider Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema July 22, 2026 6:50 AM - Globe NewsWire Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema July 22, 2026 6:50 AM - StreetInsider Form 4 Pharvaris N.V. For: Jul 13 Filed by: Modig Berndt July 15, 2026 1:08 PM - SEC Filing Wells Fargo Starts Pharvaris B.V. (PHVS) at Overweight July 15, 2026 5:11 AM - StreetInsider Form 4 Pharvaris N.V. For: Jul 11 Filed by: Lu Peng July 14, 2026 3:47 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Modig Berndt July 13, 2026 4:39 PM - SEC Filing FDA accepts Pharvaris NDA for oral HAE attack treatment deucrictibant July 6, 2026 6:50 AM - StreetInsider Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks July 6, 2026 6:50 AM - StreetInsider Form 4 Pharvaris N.V. For: Jun 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus July 1, 2026 7:06 PM - SEC Filing Form 4 Pharvaris N.V. For: Jun 29 Filed by: Lesage Anne July 1, 2026 7:03 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lesage Anne June 30, 2026 4:37 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lesage Anne June 30, 2026 4:37 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus June 30, 2026 4:36 PM - SEC Filing Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lesage Anne June 29, 2026 6:41 PM - SEC Filing Form 4 Pharvaris N.V. For: Jun 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus June 29, 2026 6:18 PM - SEC Filing Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lu Peng June 29, 2026 6:18 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus June 29, 2026 4:49 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lesage Anne June 29, 2026 4:46 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lesage Anne June 29, 2026 4:46 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lu Peng June 26, 2026 4:31 PM - SEC Filing Form 6-K Pharvaris N.V. For: Jun 26 June 26, 2026 11:27 AM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lu Peng June 25, 2026 4:25 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lesage Anne June 25, 2026 4:24 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lesage Anne June 25, 2026 4:24 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus June 25, 2026 4:24 PM - SEC Filing Pharvaris B.V. (PHVS) PT Raised to $46 at Morgan Stanley June 25, 2026 8:53 AM - StreetInsider Form 4 Pharvaris N.V. For: Jun 18 Filed by: Lu Peng June 23, 2026 5:07 PM - SEC Filing Form 144 Pharvaris N.V. Filed by: Lu Peng June 18, 2026 4:28 PM - SEC Filing Full Article List